{
    "clinical_study": {
        "@rank": "10182", 
        "brief_summary": {
            "textblock": "The purpose of the study is to measure tumor response rates for three schedules of\n      Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or\n      metastatic non small cell lung cancer who have received no prior chemotherapy regimen."
        }, 
        "brief_title": "Comparing 3 Schedules of Alimta Plus Gemzar", 
        "condition": [
            "Carcinoma, Non-Small-Cell Lung", 
            "Lung Neoplasms", 
            "Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of non-small lung cancer\n\n          -  No prior chemotherapy\n\n          -  Able to care for self\n\n        Exclusion Criteria:\n\n          -  An ongoing infection\n\n          -  Pregnancy or breast feeding\n\n          -  Other serious medical condition\n\n          -  Cancer that has spread to the brain\n\n          -  Inability to take folic acid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 1, 2002", 
        "id_info": {
            "nct_id": "NCT00034606", 
            "org_study_id": "5115", 
            "secondary_id": "H3E-MC-JMEL"
        }, 
        "intervention": {
            "intervention_name": "Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Pemetrexed"
            ]
        }, 
        "keyword": [
            "Lung cancer", 
            "cancer", 
            "neoplasm", 
            "non-small", 
            "chemotherapy"
        ], 
        "lastchanged_date": "July 18, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034606"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2006"
    }, 
    "geocoordinates": {
        "null": "44.022 -92.47"
    }
}